---
title: "TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of SurVeil DCB"
date: "2023-11-20T14:39:24.000Z"
publishedDate: "20 novembre 2023"
summary: "Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics&#8217; TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18 November, New York, USA). The TRANSCEND trial is a prospective, multicentre, single-blind randomised controlled trial to assess the safety and efficacy of the SurVeil drug coated balloon (DCB; Surmodics) versus the [&#8230;] The post TRANSCEND 36-month data &#8220;continue to demonstrate safe and effective performance&#8221; of SurVeil DCB appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/transcend-36-month-data-continue-to-demonstrate-safe-and-effective-performance-of-surveil-dcb/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2023-11-20-transcend-36-month-data-continue-to-demonstrate-safe-and-effective-performance-of-surveil-dcb"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2023/11/Peter-Schneider.png"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/transcend-36-month-data-continue-to-demonstrate-safe-and-effective-performance-of-surveil-dcb/"
---

![TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of SurVeil DCB](https://vascularnews.com/wp-content/uploads/sites/7/2023/11/Peter-Schneider.png)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/transcend-36-month-data-continue-to-demonstrate-safe-and-effective-performance-of-surveil-dcb/*

## L’essentiel

Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics&#8217; TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18 November, New York, USA). The TRANSCEND trial is a prospective, multicentre, single-blind randomised controlled trial to assess the safety and efficacy of the SurVeil drug coated balloon (DCB; Surmodics) versus the [&#8230;] The post TRANSCEND 36-month data &#8220;continue to demonstrate safe and effective performance&#8221; of SurVeil DCB appeared first on Vascular News .

## Lien source

https://vascularnews.com/transcend-36-month-data-continue-to-demonstrate-safe-and-effective-performance-of-surveil-dcb/
